


## Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8<sup>+</sup> T cells co-expressing PD-1 and LAG-3 inhibitory receptors

### Supplementary Materials



**Supplementary Figure S1: Immune profiling of TILs in additional KRS-SCC cell lines.** KRS-SCC cell line 2 (A223-H496) or cell line 3 (B866) were injected into wt B6 recipient mice individually to validate the immune phenotypes observed in cell line 1 (A223-H500). (A–C) Representative FACS plots are shown for CD8 vs PD-1 (A), CD8 vs LAG-3 (B), PD-1 vs LAG-3 gated on CD8<sup>+</sup> (C). (D–E) Representative FACS plots are shown for CD4 vs CD25 (D) or CD4 vs FoxP3 (E) staining in different groups.

**Supplemental Table S1: Summary of *in vivo* experiment replicates and sample size**

Experiment	# of Experiments	Cell line	Sample
<b>TIL Profile</b>	Exp 1	Cell line 1	Tumor ( $n = 8$ )
	Exp 2	Cell line 1	Tumor ( $n = 6$ )
	Exp 3	Cell line 1	Tumor ( $n = 12$ )
	Exp 4	Cell line 2	Tumor ( $n = 8$ )
	Exp 5	Cell line 3	Tumor ( $n = 6$ )
	Exp 6	Cell line 2	Tumor ( $n = 6$ )
	Exp 7	Cell line 1	Tumor ( $n = 10$ )
<b>Wt vs CD8KO recipients</b>	Exp 1	Cell line 1	Control ( $n = 6$ ), CD8KO ( $n = 6$ )
	Exp 2	Cell line 1	Control ( $n = 6$ ), CD8KO ( $n = 6$ )
	Exp 3	Cell line 1	Control ( $n = 6$ ), CD8KO ( $n = 6$ )
	Exp 4	Cell line 1	Control ( $n = 12$ ), CD8KO ( $n = 12$ )
<b>Dual Inhibition</b>	Exp 1	Cell line 1	Control ( $n = 10$ ), Treatment ( $n = 14$ )
	Exp 2	Cell line 1	Control ( $n = 8$ ), Treatment ( $n = 8$ )
	Exp 3	Cell line 1	Control ( $n = 4$ ), Treatment ( $n = 6$ )